Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • ascls.org
    • ascls.org

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society for Clinical Laboratory Science
  • ascls.org
    • ascls.org
  • My alerts
  • Log in
  • My Cart
American Society for Clinical Laboratory Science

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Info for
    • Authors
    • Reviewers
  • About Us
    • About Us
    • Conflict of Interest
    • Informed Consent
    • Human and Animal Rights
  • More
    • Alerts
    • Feedback
    • Folders
  • Follow ASCLS on Twitter
  • Visit ASCLS on Facebook
  • Follow ASCLS on Instagram
  • RSS Feed
IntroductionFocus: Cardiovascular Risk Assessment

Introduction

Kevin F. Foley
American Society for Clinical Laboratory Science October 2009, 22 (4) 223-225; DOI: https://doi.org/10.29074/ascls.22.4.223
Kevin F. Foley
is a clinical chemist, Kaiser Permanente NW Laboratories, Portland, OR
PhD, MT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kevin.f.foley@kp.org
  • Article
  • Info & Metrics
  • PDF
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

  1. Kevin F. Foley, PhD, MT⇑
    1. is a clinical chemist, Kaiser Permanente NW Laboratories, Portland, OR
  1. Address for Correspondence: Kevin F. Foley PhD, MT, Kaiser Permanente NW Laboratories, 13705 NE Airport Way Portland, OR, 97230 503 258-6902, kevin.f.foley{at}kp.org.

Extract

There is no area of laboratory medicine that requires more interpretive knowledge than cardiovascular risk assessment. The clinical laboratory has moved far from the days when triglycerides, total cholesterol, HDL and a calculated LDL were the only laboratory tests that could be used to assess the cardiovascular risk for patients. In this series we will look at four different topics in cardiovascular laboratory medicine.

One can think of cardiovascular laboratory medicine as having two arms; tests used to assess cardiovascular risk, and tests used to assess myocardial infarct. Of course these two arms overlap significantly in that myocardial infarct is a major cardiovascular event for which we want to gauge risk. Measuring markers such as CK-MB or troponins allows us to confirm or rule out myocardial infarction. In contrast, risk markers are a tool we can use to assess a person's risk for cardiac morbidity or mortality. When considering markers for myocardial infarct, most laboratorians know that CK-MB and troponin can provide valuable diagnostic and sometimes even prognostic information. But is it time to phase-out CK-MB testing given the performance and demonstrated superiority of troponin testing? In this series we review the use of troponin and CK-MB in contemporary laboratory practice.

This journal also discusses the value and supporting data for genetic assessment of patients at risk for coronary artery disease. Clinical laboratorians are no doubt aware that a genetic component exists when predicting cardiovascular risk. The linkages, specific genes and utility of genetic testing with regard to cardiovascular disease…

    INDEX TERMS
  • Cardiovascular risk
  • proBNP
  • CRP
  • CAD
  • ©Copyright 2009 American Society for Clinical Laboratory Science Inc. All rights reserved.
PreviousNext
Back to top

In this issue

American Society for Clinical Laboratory Science: 22 (4)
American Society for Clinical Laboratory Science
Vol. 22, Issue 4
Fall 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Society for Clinical Laboratory Science.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Introduction
(Your Name) has sent you a message from American Society for Clinical Laboratory Science
(Your Name) thought you would like to see the American Society for Clinical Laboratory Science web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Introduction
Kevin F. Foley
American Society for Clinical Laboratory Science Oct 2009, 22 (4) 223-225; DOI: 10.29074/ascls.22.4.223

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Introduction
Kevin F. Foley
American Society for Clinical Laboratory Science Oct 2009, 22 (4) 223-225; DOI: 10.29074/ascls.22.4.223
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Genetic Markers for Coronary Artery Disease
  • Heart Failure and B-Type Natriuretic Protein
Show more Focus: Cardiovascular Risk Assessment

Similar Articles

Keywords

  • Cardiovascular risk
  • proBNP
  • CRP
  • CAD

© 2025 The American Society for Clinical Laboratory Science

Powered by HighWire